Abstract
Purpose
To quantify the in vivo role of P-glycoprotein (P-gp) in the pharmacokinetics of methadone after intravenous and oral administration, using valspodar as a P-gp inhibitor.
Materials and Methods
Methadone plasma concentrations after intravenous (0.35 mg/kg) and oral (6 mg/kg) administration were analyzed, in absence and presence of valspodar, using nonlinear mixed effects modeling (NONMEM V). Non-parametric bootstrap analysis and posterior predictive check were employed as model evaluation techniques.
Results
The pharmacokinetics of methadone in the rat was successfully modeled using a two-compartmental model with a linear elimination from the central compartment and a first-order absorption process with lag time. Valspodar increased methadone F by 122% (95%CI: 34–269%) and decreased the V c and V p by 35% (95%CI: 16–49%) and 81% (95%CI: 63–93%), respectively. No effect of valspodar on other pharmacokinetic parameters was discernible. The non-parametric bootstrap analysis confirmed the absence of bias on the parameter estimates, and visual predictive check evidence the adequacy of the model to reproduce the observed time course of methadone plasma concentrations.
Conclusion
Valspodar increased methadone’s bioavailability as consequence of P-gp inhibition, which resulted in an increased analgesic effect of methadone.
Similar content being viewed by others
References
S. Mercadante, A. Casuccio, F. Fulfaro, L. Groff, R. Boffi, P. Villari, V. Gebbia, and C. Ripamonti. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J. Clin. Oncol. 19:2898–2904 (2001).
C. Ripamonti, and M. Bianchi. The use of methadone for cancer pain. Hematol. Oncol. Clin. North Am. 16:543–555 (2002).
NIH Consensus Conference. Effective medical treatment of opiate addiction. JAMA 280:1936–1943 (1998).
P. G. Barnett, and S. S. Hui. The cost-effectiveness of methadone maintenance. Mt. Sinai J. Med. 67:365–374 (2000).
M. J. Kreek, and F. J. Vocci. History and current status of opioid maintenance treatments: blending conference session. J. Subst. Abuse Treat. 23:93–105 (2002).
M. J. Garrido, and I. F. Troconiz. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. J. Pharmacol. Toxicol. 42:61–66 (1999).
C. B. Eap, T. Buclin, and P. Baumann. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin. Pharmacokinet. 41:1153–1193 (2002).
R. L. Juliano, and V. Ling. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455:152–162 (1976).
S. E. Bates. “ABC proteins from bacteria to man”. In I. B. Holland, S. P. C. Cole, K. Kuchler, and F. Higgings (eds.), Elsevier Science, London, 2003.
A. Ayrton, and P. Morgan. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 31:469–497 (2001).
F. Thiebaut, T. Tsuruo, H. Hamada, M. M. Gottesman, I. Pastan, and M. C. Willingham. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. 84:7735–7738 (1987).
C. Cordon-Cardo, J. P. O’Brien, J. Boccia, D. Casals, J. R. Bertino, and M. R. Melamed. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J. Histochem. Cytochem. 38:1277–1287 (1990).
D. Balayssac, N. Authier, A. Cayre, and F. Coudore. Does inhibition of P-glycoprotein lead to drug–drug interactions? Toxicol. Lett. 156:319–329 (2005).
R. Callaghan, and R. Riordan. Synthetic and natural opiates interact with P-glycoprotein in multidrug resistant cells. BioChem. 268:1659–1664 (1993).
M. Rodríguez, I. Ortega, I. Soengas, E. Suárez, J. C. Lukas, and R. Calvo. Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J. Pharm. Pharmacol. 56:367–374 (2004).
E. D. Kharasch, C. Hoffer, and D. Whittington. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br. J. Clin. Pharmacol. 57:600–610 (2004).
M. A. Carlos, P. Du Souich, R. Carlos, E. Suarez, J. C. Lukas, and R. Calvo. Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. J. Pharm. Sci. 91:1627–1638 (2002).
F. Bourasset, S. Cisternino, J. Temsamani, and J. M. Scherrmann. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood–brain barrier. J. Neurochem. 86:1564–1567 (2003).
M. Achira, H. Suzuki, K. Ito, and Y. Sugiyama. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci. 1:E18 (1999).
P. Atadja, T. Watanabe, H. Xu, and D. Cohen. PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev. 17:163–168 (1998).
I. Kawahara, Y. Kato, H. Suzuki, M. Achira, K. Ito, C. L. Crespi, and Y. Sugiyama. Selective inhibition of human cytochrome P450 3A4 N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)- (1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-b]pyridin-5-yl) methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab. Dispos. 28:1238–1243 (2000).
M. J. Garrido, M. Valle, R. Calvo, and I. F. Troconiz. Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J. Pharmacol. Exp. Ther. 288:179–187 (1999).
S. Song, H. Suzuki, R. Kawai, C. Tanaka, I. Akasaka, and Y. Sugiyama. Dose-dependent effects of PSC 833 on its tissue distribution and on the biliary excretion of endogenous substrates in rats. Drug Metab. Dispos. 26:1128–1133 (1998).
K. Wolff, A. W. Hay, and D. Raistrick. Plasma methadone measurements and their role in methadone detoxification programs. Clin. Chem. 38:420–425 (1992).
S. L. Beal, A. Boeckmann, and L. B. Sheiner. NONMEM users guides—part I–VIII, NONMEM Project Group C2555. University of California at San Francisco, San Francisco, (1988–1998).
M. Rodriguez, I. Ortega, I. Soengas, N. Leal, E. Suárez, R. Calvo, and J. C. Lukas. Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding. J. Pharm. Sci. 93:2836–2850 (2004).
P. Girard. Data transformation and Parameter Transformations in NONMEM. 11th PAGE Meeting, Paris, France, 2002.
K. Jolling, J. J. Ruixo, A. Hemeryck, V. Piotrovskij, and T. Greway. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J. Pharm. Sci. 93:3027–3038 (2004).
U. Wahlby, E. N. Jonsson, and M. O. Karlsson. Comparison of stepwise covariate model building strategies in population pharmacokinetic–pharmacodynamic analysis. AAPS PharmSci. 4:E27 (2002).
B. Efron, and R. Tibshirani. An Introduction to the Bootstrap. Chapman and Hall, London, (1993).
Y. Yano, S. L. Beal, and L. B. Sheiner. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J. Pharmacokinet. Pharmacodyn. 28:171–192 (2001).
J. Hing, S. G. Woolfrey, D. Greenslade, and P. M. C. Wright. Distinguishing animal subsets in toxicokinetic studies: comparison of non-linear mixed effects modelling with non-compartmental methods. J. Appl. Toxicol. 22:437–443 (2002).
F. Bouzom, C. Laveille, H. Merdjan, and R. Jochemsen. Use of non-linear mixed effects modeling for the meta-analysis of preclinical pharmacokinetic data: application to S20342 in the rat. J. Pharm. Sci. 89:603–613 (2000).
R. Bouer, L. Barthe, C. Philibert, C. Tournaire, J. Woodley, and G. Houin. The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam. Clin. Pharmacol. 13:494–500 (1999).
J. van Asperen, O. van Tellingen, A. Sparreboom, A. H. Schinkel, P. Borst, W. J. Nooijen, and J. H. Beijnen. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer. 76:1181–1183 (1997).
M. Ballent, A. Lifschitz, G. Virkel, J. Sallovitz, and C. Lanusse. Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: in vitro and in vivo assessments. Drug Metab. Dispos. 34:457–463 (2006).
E. Bostrom, U. S. Simonsson, and M. Hammarlund-Udenaes. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J. Pharm. Sci. 94:1060–1066 (2005).
B. Lalovic, B. Phillips, L. L. Risler, W. Howald, and D. D. Shen. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 32:447–454 (2004).
K. Bogman, F. Erne-Brand, J. Alsenz, and J. Drewe. The role of surfactants of active transport mediated by multidrug resistance proteins. J. Pharm. Sci. 92:1250–1261 (2003).
H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 36:16–24 (1998).
L. van Zuylen, J. Verweij, K. Nooter, E. Brouwer, G. Stoter, and A. Sparreboom. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin. Cancer Res. 6:2598–2603 (2000).
S. Callies, D. P. de Alwis, J. G. Wright, A Sandler, M Burgess, and L. Aarons. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother. Pharmacol. 51:107–118 (2003).
J. L. Gabrielsson, P. Johansson, U. Bondesson, and L. K. Paalzow. Analysis of methadone disposition in the pregnant rat by means of a physiological flow model. J. Pharmacokinet. Biopharm. 13:355–372 (1985).
M. van der Deen, E. G. de Vries, W. Timens, R. J. Scheper, H. Timmer-Bosscha, and D. S. Postma. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 6:59 (2005).
M. Quin, M. Nilsson, and S. Oie. Decreased elimination of drug in the presence of alpha-1-acid glycoprotein is related to a reduced hepatocyte uptake. J. Pharmacol. Exp. Ther. 269:1176–1181 (1994).
J. Liu, and L. J. Brunner. Chronic cyclosporine administration induces renal P-glycoprotein in rats. Eur. J. Pharmacol. 418:127–132 (2001).
Acknowledgements
Support was from University of the Basque Country (IO) and the Basque Government scholarship (MR). We are thankful to Mr. Jokin Lodos for his careful animal surgical procedures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ortega, I., Rodriguez, M., Suarez, E. et al. Modeling Methadone Pharmacokinetics in Rats in Presence of P-glycoprotein Inhibitor Valspodar. Pharm Res 24, 1299–1308 (2007). https://doi.org/10.1007/s11095-007-9251-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-007-9251-2